Ampholip Special Precautions

Systemic Fungal Infections: Ampholip should not be used for treating common or superficial, clinically inapparent fungal infections that are detectable only by positive skin or serologic tests.
Renal Disease: Since Ampholip is a potentially nephrotoxic drug, monitoring of renal function should be performed before initiating treatment and during the treatment. This is particularly important in patients with pre-existing renal disease, who have already experienced renal failure, or in patients receiving nephrotoxic medications. Laboratory evaluation of serum electrolytes, particularly potassium should be performed regularly before and during therapy. Cases of hyperkalaemia (some of them leading to cardiac arrhythmias and cardiac arrest) have been reported. Some of them occurred in patients with renal impairment, or after potassium supplementation in patients with previous hypokalaemia.
Liver Disease: Patients with concurrent hepatic impairment due to infection, graft-versus-host disease, other liver disease or administration of hepatotoxic drugs have been successfully treated with Ampholip. In cases where serum bilirubin, alkaline phosphatase or serum transaminases increased, factors other than Ampholip were present and possibly accounted for the abnormalities. These factors included infection, hyperalimentation, concomitant hepatotoxic drugs and graft-versus-host disease.
Effect on Ability to Drive and Use Machines: Ampholip is unlikely to affect the ability of an individual to drive or use machines, since adverse reactions are usually infusion-related. However, the clinical condition of patients who require Ampholip generally precludes driving or operating machinery.